Back to Search
HENRY PITOT, M.D.
M.D.
Medical Oncology Physician
NPI: 1700865102Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
30991(MN)
Research & Publications (20)
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
PMID 16328416·Cancer Chemother Pharmacol·2006
3-trial
A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.
PMID 11895900·Clin Cancer Res·2002
3-trial
Future directions in adjuvant therapy for stage III colon carcinoma.
PMID 11301838·Oncology (Williston Park)·2001
6-review
A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma.
PMID 11042563·Cancer·2000
3-trial
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
PMID 10873073·Clin Cancer Res·2000
3-trial
Disruption of estrogen receptor signaling enhances intestinal neoplasia in Apc(Min/+) mice.
PMID 19520794·Carcinogenesis·2009
7-preclinical
Predominant modifier of extreme liver cancer susceptibility in C57BR/cdJ female mice localized to 6 Mb on chromosome 17.
PMID 19255062·Carcinogenesis·2009
7-preclinical
Long-lived Min mice develop advanced intestinal cancers through a genetically conservative pathway.
PMID 19584276·Cancer Res·2009
7-preclinical
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
PMID 19380443·J Clin Oncol·2009
3-trial
Nitric oxide regulates tumor cell cross-talk with stromal cells in the tumor microenvironment of the liver.
PMID 18755846·Am J Pathol·2008
7-preclinical
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
PMID 19047126·Clin Cancer Res·2008
3-trial
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
PMID 19001325·J Clin Oncol·2008
4-observational
Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741.
PMID 19073970·Clin Cancer Res·2008
2-rct
The pleiotropic phenotype of Apc mutations in the mouse: allele specificity and effects of the genetic background.
PMID 18723878·Genetics·2008
7-preclinical
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
PMID 18278438·Invest New Drugs·2008
3-trial
p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers.
PMID 18413729·Cancer Res·2008
7-preclinical
CpG PatternFinder: a Windows-based utility program for easy and rapid identification of the CpG methylation status of DNA.
PMID 17907576·Biotechniques·2007
8-other
Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial.
PMID 19065716·J Gastrointest Cancer·2007
3-trial
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
PMID 17687151·J Clin Oncol·2007
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 1ST ST SW
ROCHESTER, MN 55905 - Phone
- (507) 284-2511
Quick Facts
- NPI
- 1700865102
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile